AI Feeds People Incorrect Ophthalmology Information
ChatGPT, Google Bard, and Bing Chat struggle with recommending practicing nearby ophthalmologists and disproportionate against females.
Faricimab Outperforms Aflibercept in Hyperreflective Foci Resolution in DME
The post hoc analysis of the phase 3 YOSEMITE/RHINE trials may support the therapeutic role of dual Ang-2/VEGF-A inhibition with faricimab for DME.
Treating Geographic Atrophy Every Other Month is The More Cost-Effective Option
For people with geographic atrophy, taking pegcetacoplan every other month (the EOM treatment) is more cost-effective than taking the medication every month (the EM treatment).
Patients Maintain Longer Breaks Between Treatment with Improvements in Fluid Levels
In the study from AAO 2023, patients with neovascular AMD who are on aflibercept injection treatment continued their treatments >12 weeks or 16 weeks.
Faricimab Significantly Reduces Macular Leakage Versus Aflibercept in DME
A post hoc analysis of the phase 3 YOSEMITE and RHINE trials found significantly more patients had leakage resolution with faricmab than with aflibercept at Week 16.
YOSEMITE/RHINE: Faricimab Treat-and-Extend Shows Durability in DME Over 2 Years
Results from the phase 3 YOSEMITE and RHINE trials show more than half of faricimab treat-and-extend patients met the criteria for a potential every-20-week dosing extension.
Robert Cionni, MD: Innovations in Drug Delivery for Glaucoma Treatment
The SpyGlass IOL platform showcased a 45% drop in mean intraocular pressure at 3 months in first-in-human glaucoma trial.
David Lally, MD: Insights into Safety Data on EYP-1901 for nAMD
Safety data of the bioerodible sustained delivery intravitreal anti-VEGF treatment indicate no ocular or systemic serious adverse events with mild adverse events.
David Boyer, MD: Significance of 24-Month Safety Data on Pegcetacoplan in GA
A discussion into safety data from the Phase 3 DERBY and OAKS trials on pegcetacoplan with Dr. Boyer at AAO 2022.
AI Algorithm May Help Identify Eligibility for Diabetic Retinopathy Clinical Trials
New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.
Bevacizumab Linked to Greater ROP Retreatment than Ranibizumab
A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.
Jennifer Lim, MD: Extended Durability in nAMD, DME Achieved with Faricimab
Faricimab treatment for both DME and nAMD was able to reliably get to 16 week dosing in 60% of eyes from YOSEMITE and RHINE and TENAYA and LUCERNE.
Proposed Aflibercept Biosimilar Provides Comparable Efficacy, Safety for DME
Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.
Faricimab Exhibits Durable Efficacy in nAMD Treatment in TENAYA and LUCERNE
The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.
Dilsher Dhoot, MD: Analysis of OTX-TKI Implant Shows Promise for Wet AMD Treatment
The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.
Rishi Singh, MD: Efficacy of Pegcetacoplan for GA Based on 24-Month Data
A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.
Charles Wykoff, MD, PhD: Shifting the Treatment Paradigm with Pegcetacoplan for GA
A look into major takeaways on efficacy, safety and functional data from the DERBY and OAKS trials on pegcetacoplan.
Peter J Kertes, MD: Insights into the TALON Trial on Brolucizumab Versus Aflibercept
Brolucizumab was deemed superior to aflibercept in treatment naive patients with neovascular age-related macular degeneration.
Initially Costlier, Ranibizumab PDS May Be More Cost-Effective Long-Term for nAMD Patients
New AAO 2022 data show the novel treatment administration may eventually save patients money versus standard anti-VEGF injfections.
EYP-1901 Safe, Tolerable for nAMD at 6 Months
New findings show the investigative single-dose agent is safe and associated with reduced rescue-dose anti-VEGF treatment.
Anti-VEGF Treatments Do Not Differ in Long-Term Intraocular Pressure
Comparison of 12- and 24-month regimens of common nAMD treatment show little difference in the common adverse event in patient eyes.
Two-Year Findings on Brolucizumab for nAMD Reported After MERLIN Trial Termination
Brolucizumab every four weeks met efficacy end points versus aflibercept at end of MERLIN study, but with higher incidences of intraocular inflammation.
Avacincaptad Pegol for GA Meets Primary Efficacy Endpoint in GATHER2 Trial
GATHER2 reports a 14.3% reduction in mean rate of growth in GA area over 12 months with avacincaptad pegol compared to sham.
Biosimilar SB15 Indicates Equivalent Efficacy to Aflibercept in nAMD Treatment
The least squares mean change from baseline in BCVA at Week 8 was 6.7 letters for SB15 versus 6.6 letters for aflibercept.
Theodore Leng, MD: Characterizing the Definition, Rates of Intermediate Dry AMD
Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.
José-Alain Sahel, MD: Safety, Efficacy of Optogenetic Treatment for Retinitis Pigmentosa
At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.
Robert L. Avery, MD Highlights Results on RGX-314 For the Treatment Of Wet AMD
Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results
Dilsher S. Dhoot, MD: Efficacy of Brolucizumab in Treatment of Diabetic Macular Edema
Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.
Arshad Khanani, MD Discusses Adverse Ocular Events After Brolucizumab Treatment
Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.
Veeral Sheth, MD: Identifying Durability, Safety of GB-102 in Wet AMD Treatment
Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.
